Our Firm is investigating claims on behalf of a number of women who allegedly experienced the spread of uterine sarcomas and other cancers due to uterine morcellation, so we are watching developments related to this issue with great interest.
New York, New York (PRWEB) January 09, 2015
Bernstein Liebhard LLP notes that health regulators in the United Kingdom are expected to soon release new guidance regarding the use of power morcellators (http://www.morcellatorlawsuit2015.com) in minimally-invasive hysterectomies and fibroid removal surgeries. According to a posting on the website for the U.K.’s National Institute for Health and Care Excellence (NICE), the agency’s consultation period for the matter ended on November 25th, 2014.* An earlier posting indicated that NICE would release new uterine morcellation guidance in February 2015.**
“Our Firm is investigating claims on behalf of a number of women who allegedly experienced the spread of uterine sarcomas and other cancers due to uterine morcellation, so we are watching developments related to this issue with great interest. Regulators have already acted in the U.S. and Canada, and we look forward to the announcement of new guidance in the U.K,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is providing free legal consultations to women who were diagnosed with advanced uterine cancers following uterine morcellation.
Power Morcellator Cancer Warnings
Power morcellators are used in minimally-invasive uterine surgeries to cut up tissue into small pieces so that it can be removed from the body via a small abdominal incision. The U.S. Food & Drug Administration (FDA) has been reviewing the association between uterine morcellation and cancer since April 2014, when it first discouraged doctors from using the devices. On November 24th, the agency issued a second alert that warned against the use of the devices in most women, and asked power morcellator manufacturers to add a new black box warning – the strongest possible safety notice – regarding this life-threatening complication to their labels.
In May 2013, Health Canada advised hospitals to consider treatment alternatives that do not require power morcellation for women with symptomatic uterine fibroids because of their potential to spread undetected uterine cancer cells.*** Last month, the agency issued a new alert that also indicated it would seek new warning labels for power morcellators. Like the FDA, Health Canada also advised against the use of uterine morcellation in the majority of women.****
Alleged victims of uterine sarcoma or other cancers allegedly spread via power morcellation may be entitled to compensation for their injury-related damages. To learn more about filing a morcellator lawsuit, please visit Bernstein Liebhard LLP's website. To obtain a free legal review, please call 800-511-5092.
*http://www.nice.nhs.uk/guidance/index.jsp?action=folder&o=69556, NICE, November 25, 2014
**nice.org.uk/guidance/ipg486, NICE, April 2014
***healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/39409a-eng.php, Health Canada, May 7, 2014
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP